SBIR-STTR Award

Enhanced Adp Immunoassay For Multimode Kinase Detection
Award last edited on: 6/28/10

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$192,952
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Robert G Lowery

Company Information

Bellbrook Labs LLC (AKA: Bell Brook Labs LLC)

5500 Nobel Drive Suite 250
Madison, WI 53711
   (608) 443-2400
   info@bellbrooklabs.com
   www.bellbrooklabs.com
Location: Multiple
Congr. District: 02
County: Dane

Phase I

Contract Number: 1R43GM088945-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2009
Phase I Amount
$192,952
Kinases are the most intensively screened class of enzymes being targeted for therapeutic intervention because of their central role in regulating the function of other biomolecules. Strategies for developing selective kinase inhibitors are evolving rapidly, creating a demand for more flexible methods for measuring kinase activity in high throughput screening campaigns. Specifically, generic assays that can accommodate ATP concentrations spanning the physiological range are badly needed. Under separate SBIR funding, BellBrook Labs developed and commercialized a novel kinase enzyme assay method called Transcreener(R) that relies on selective immunodetection of ADP, thus enables detection of any kinase regardless of the acceptor substrate. The assay has been widely adopted by pharmaceutical industry, and licensed by leading drug discovery service providers, providing a significant revenue stream to BellBook. Despite its technical advantages and commercial success, significant drawbacks of the method include the need to adjust antibody concentration to accommodate different ADP levels, and a negative signal in response to ADP because of the competitive nature of the assay. To overcome these limitations, we will collaborate with Dr. Bruce Hammock at University of California, Davis to develop phage-borne peptides that bind specifically to the ADP-antibody immune complex. The use of these phage-peptides in a trivalent immune complex is expected to increase the selectivity for ADP detection vs. ATP, thereby overcoming the major limitation with the Transcreener platform. In addition, the resulting noncompetitive immunoassay, called a Phage Anti-Immune Complex (PHAIA), will generate a signal that is directly proportional to product formation in either homogenous (e.g., TR-FRET), or solid phase (e.g., ELISA) formats, thus greatly extending the flexibility and applicability of the method.

Public Health Relevance:
Kinases are one of the largest families of proteins in humans, and their malfunction is involved in many types of diseases, especially cancers, inflammation-related diseases. This proposal seeks to produce improved tools for identifying selective kinase inhibitors that can be used as drugs to treat kinase-related diseases.

Public Health Relevance Statement:
Narrative Kinases are one of the largest families of proteins in humans, and their malfunction is involved in many types of diseases, especially cancers, inflammation-related diseases. This proposal seeks to produce improved tools for identifying selective kinase inhibitors that can be used as drugs to treat kinase-related diseases.

NIH Spending Category:
Biotechnology

Project Terms:
ATP phosphohydrolase; ATP-protein phosphotransferase; ATPase; Adenosine Triphosphatase; Adenosinetriphosphatase; Adopted; Antibodies; Antigen-Antibody Complex; Assay; Bacteriophages; Binding; Binding (Molecular Function); Bioassay; Biologic Assays; Biological Assay; California; Cancers; Carbohydrates; Cell Communication and Signaling; Cell Signaling; Chimp; Chimpanzee; Clinical Trials, Phase I; Communities; Complex; Coupled; Detection; Development; Disease; Disorder; Drug Industry; Drugs; Drugs, Nonproprietary; EC 2.7; ELISA; Early-Stage Clinical Trials; Enzyme-Linked Immunosorbent Assay; Enzymes; Family; Figs; Figs - dietary; Fluorescence; Fluorescence Polarization; Funding; Generic Drugs; Genetic Alteration; Genetic Change; Genetic defect; Glycine cleavage system P-protein; Glycine dehydrogenase (decarboxylating); Haptens; High Throughput Assay; Human; Human, General; IC50; INFLM; Immune Complex; Immune Precipitation; Immunoassay; Immunoprecipitation; Industry, Pharmaceutic; Inflammation; Inhibitory Concentration 50; Intracellular Communication and Signaling; Kinases; Label; Laboratories; Left; Libraries; Licensing; Link; Lipids; Malignant Neoplasms; Malignant Tumor; Man (Taxonomy); Man, Modern; Marketing; Measures; Medication; Methods; Molecular Interaction; Mutation; Nature; Nucleic Acids; Nucleotides; Output; P-protein; P-protein, glycine decarboxylase; PKA inhibitor; PROV; Pan; Pan Genus; Pan Species; Peptide Library; Peptides; Phage Display; Phages; Pharmaceutic Preparations; Pharmaceutical Agent; Pharmaceutical Industry; Pharmaceutical Preparations; Pharmaceuticals; Pharmacologic Substance; Pharmacological Substance; Phase; Phase 1 Clinical Trials; Phase I Clinical Trials; Phase I Study; Phosphotransferases; Physiologic; Physiological; Principal Investigator; Process; Programs (PT); Programs [Publication Type]; Protein Family; Protein Kinase; Proteins; Provider; Publishing; Radiation Dosimetry; Radiometry; Reaction; Reagent; Relative; Relative (related person); Research; Role; SBIR; SBIRS (R43/44); Screening procedure; Services; Signal Transduction; Signal Transduction Systems; Signaling; Small Business Innovation Research; Small Business Innovation Research Grant; Solid; Stream; Structure-Activity Relationship; Tag; Testing; Therapeutic Intervention; Tracer; Transphosphorylases; Universities; bacterial virus; base; biological signal transduction; chemical structure function; disease/disorder; drug discovery; drug/agent; flexibility; gene product; generic; genome mutation; glycine decarboxylase; glycogen synthase a kinase; high throughput screening; hydroxyalkyl protein kinase; improved; intervention therapy; kinase inhibitor; malignancy; neoplasm/cancer; novel; phase 1 study; phase 1 trial; phase I trial; phosphorylase b kinase kinase; programs; protocol, phase I; public health relevance; radioassay; response; screening; screenings; small molecule; social role; structure function relationship; success; tool; user-friendly

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----